Oracle
ORCL
Vale SA
VALE
Toll Brothers
TOL
4
D.R. Horton
DHI
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
HUMA Humacyte
- 1.460
- +0.020+1.39%
Close Apr 28 16:00 ET
226.47MMarket Cap-1.16P/E (TTM)
1.505High1.430Low1.33MVolume1.460Open1.440Pre Close1.94MTurnover1.08%Turnover RatioLossP/E (Static)155.12MShares9.97052wk High-4.29P/B180.24MFloat Cap1.15052wk Low--Dividend TTM123.45MShs Float17.450Historical High--Div YieldTTM5.21%Amplitude1.150Historical Low1.463Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Humacyte Stock Forum
seems to finds a stable supporrt level at 1.40
good for daytrade take profits
if FDA approval disappears then gg i guess
Humacyte Q4 Earnings: 34 Hospitals Eye New FDA-Approved Vascular Treatment
Investing.com -- Dr. Laura Niklason, President and CEO of Humacyte, Inc. (NASDAQ:HUMA), responded to a New York Times (NYSE:NYT) article that questioned the FDA’s approval of Symvess for commercial sales earlier this week. Niklason had previously withheld comment due to the company b...
No comment yet